Page 5 - Liposome Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Innocan Pharma Corporation: Innocan Pharma Announces Closing of Private Placement
Herzliya, Israel and Calgary, Alberta (Newsfile Corp. - December 31, 2020) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the Company or Innocan ) is pleased to announce that it has today closed a non-brokered private placement offering of 10,294,800 units of Innocan (the Units ) at a price of $0.23 per Units for aggregate gross proceeds of $2,367,804 (the Offering ).
All Common Shares and Warrants issued pursuant to the Offering will be subject to a four month statutory hold period commencing from the closing date under applicable securities laws.
Each Unit consists of one common share in the capital of the Company ( Common Share ) and one-half of one common share purchase warrant ( Warrant ). Each whole Warrant entitles the holder to purchase one Common Share at a price of $0.35 for a period of three years from the date of issuance. ....

Israel General , Tel Aviv , Iris Bincovich , Company Or Innocan , Liposome Research Of The Hebrew University , Innocan Pharma Corporation , Head Of The Laboratory Membrane , Innocan Pharma Ltd , Hebrew University Of Jerusalem , Canadian Securities Exchange , Alberta Newsfile Corp , Company Common Share , Tel Aviv University , Pharma Corporation , Common Shares , Common Share , Chief Executive Officer , Innocan Pharma , Innocan Israel , Hebrew University , Professor Berenholtz , Liposome Research , இஸ்ரேல் ஜநரல் , தொலைபேசி அவிவ் , தலை ஆஃப் தி ஆய்வகம் சவ்வு , ஹீப்ரு பல்கலைக்கழகம் ஆஃப் ஏருசலேம் ,